Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867143 | 0.85 | ALOX15 (0.31) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL307010 | 0.85 | — | — | |
| SCHEMBL5639011 | 0.85 | ALOX15 (0.35) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL11061010 | 0.84 | ALOX15 (0.36) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL995487 | 0.84 | ALOX15 (0.36) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL9115301 | 0.83 | GABRR1 (0.37) | — | |
| SCHEMBL5221873 | 0.80 | ALOX15 (0.33) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL6239265 | 0.80 | GRIK1 (0.41) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL869883 | 0.80 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL5187828 | 0.79 | ALOX15 (0.39) | ALOX15BLMPMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200056159-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-02-20 | — | — | US | claimed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| CN-1810832-A | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity | AMGEN INC (US) | 2006-08-02 | — | — | CN | claimed |
| CN-1250721-C | Mimetic dimeric thrombopoietin peptides that bind to MP1 receptor and have thrombopoietic activity | AMGEN INC (US) | 2006-04-12 | — | — | CN | claimed |
| CN-1325447-A | Mimetic dimeric thrombopoietin peptides that bind to MP1 receptor and have thrombopoietic activity | AMGEN INC (US) | 2001-12-05 | — | — | CN | claimed |
| CN-117430095-A | Preparation method of hydroxylamine aqueous solution | 浙江锦华新材料股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-3737420-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200056159-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-02-20 | — | — | US | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| CN-109715187-A | Insulin glargine and trien (TETA) | 艾瑞克有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109715186-A | Insulin glargine | 艾瑞克有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20150216948-A1 | CYTOCHROME P450 SUICIDE GENE SYSTEM | HANENBERG HELMUT (US) | 2015-08-06 | — | — | US | disclosed |
| EP-0796335-A1 | PRODUCTION OF PEPTIDES USING RECOMBINANT FUSION PROTEIN CONSTRUCTS | BIONEBRASKA, INC. (US) | 1997-09-24 | — | — | EP | disclosed |
| CN-1151761-A | Subtilisin BPN' variants with reduced adsorption and increased hydrolysis | PROCTER & GAMBLE (US) | 1997-06-11 | — | — | CN | disclosed |
| US-5595887-A | GENE EXPRESSION, FORMING POLYPEPTIDES FOR PROTEIN PURIFICATION | BIONEBRASKA, INC. (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996017942-A9 | PRODUCTION OF PEPTIDES USING RECOMBINANT FUSION PROTEIN CONSTRUCTS | — | 1996-08-15 | — | — | WO | disclosed |
| WO-1996017942-A1 | PRODUCTION OF PEPTIDES USING RECOMBINANT FUSION PROTEIN CONSTRUCTS | BIONEBRASKA, INC. (US) | 1996-06-13 | — | — | WO | disclosed |
| EP-0539530-A4 | PURIFICATION DIRECTED CLONING OF PEPTIDES. | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0539530-A1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA, INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001707-A1 | PURIFICATION DIRECTED CLONING OF PEPTIDES | BIONEBRASKA, INC. (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200056159-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR | VSIG8, ASNS, FARSB | ALOX15 2143/4885BLM 3349/4885PMP22 4216/4885 |
| US-20150216948-A1 | CYTOCHROME P450 SUICIDE GENE SYSTEM | CYP4B1, CYP4A11, CYP2E1 | ALOX15 430/4885BLM 4530/4885PMP22 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.